Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA approval of a fixed-dose combination ophthalmic drop; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative outcomes.
FDA supplemental approval for labeling of an established ophthalmic agent; documents regulatory action without reporting clinical trial outcomes or comparative efficacy data.